HER2 overexpression in breast cancer identifies patients who benefit from trastuzumab, while PD-L1 (Programmed death-ligand 1) expression serves as a marker to guide checkpoint inhibitor therapy in immuno-oncology [1,5]. This evidence concerns the gene CD274 and breast cancer.